Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends

SG&A Expense Trends: Sarepta vs. Walgreens

__timestampSarepta Therapeutics, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 20144931500017992000000
Thursday, January 1, 20157504300022400000000
Friday, January 1, 20168374900023910000000
Sunday, January 1, 201712268200023813000000
Monday, January 1, 201820776100024694000000
Tuesday, January 1, 201928481200023557000000
Wednesday, January 1, 202031787500025436000000
Friday, January 1, 202128266000024586000000
Saturday, January 1, 202245142100027295000000
Sunday, January 1, 202348187100034205000000
Monday, January 1, 202428113000000
Loading chart...

Unlocking the unknown

SG&A Expense Trends: A Tale of Two Companies

In the ever-evolving landscape of corporate finance, understanding the trends in Selling, General, and Administrative (SG&A) expenses is crucial. This analysis compares the SG&A expenses of Sarepta Therapeutics, Inc. and Walgreens Boots Alliance, Inc. from 2014 to 2023.

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, a leader in precision genetic medicine, has seen its SG&A expenses grow by nearly 900% over the past decade, reflecting its aggressive expansion and investment in research and development. From a modest $49 million in 2014, expenses surged to $482 million by 2023, highlighting the company's commitment to innovation.

Walgreens Boots Alliance, Inc.

In contrast, Walgreens Boots Alliance, a global pharmacy giant, maintained a relatively stable SG&A expense profile, with a slight increase of about 44% from $17.7 billion in 2014 to $25.5 billion in 2023. This stability underscores its focus on operational efficiency amidst a challenging retail environment.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025